CLAIMS

1. Use of deoxypeganine, in the form of a free base or in the form of an acid addition salt, or of a derivative of deoxypeganine as long as said derivative is simultaneously inhibitor of acetylcholinesterase and of monoamine oxidase, for producing a medicament for treating a schizophrenic psychosis.

2. Use according to claim 1, characterized in that the medicament contains the active substance deoxypeganine in proportions of 0.1 to 90%-wt, preferably 2 to 20%-wt, calculated as free deoxypeganine.

3. Use according to claim 1 or 2, characterized in that said medicament has a depot effect.

4. Use according to any one of the preceding claims, characterized in that said medicament is a medicament that can be administered orally.

5. Use according to any one of claims 1 to 3, characterized in that said medicament is a medicament that can be administered parenterally.

6. Use according to claim 5, characterized in that said medicament is a medicament that can be administered transdermally.

7. Use of deoxypeganine, in the form of a free base or in the form of an acid addition salt, or of a derivative of deoxypeganine as long as said derivative is simultaneously inhibitor of acetylcholinesterase and of monoamine oxidase, for treating a schizophrenic psychosis.

8. Use according to claim 7, characterized in that the administered daily dose is in the range 0.1 to 100 mg, preferably 10 to 50 mg.

9. Use according to claim 7 or 8, characterized in that deoxypeganine is administered in a pharmaceutical preparation containing the active substance in proportions of 0.1 to 90%-wt, preferably 2 to 20%-wt, calculated as free deoxypeganine.

10. Use according to claim 9, characterized in that deoxypeganine is administered in a pharmaceutical preparation having depot effect.

11. Use according to claim 9 or 10, characterized in that deoxypeganine is administered orally.

12. Use according to claim 9 or 10, characterized in that deoxypeganine is administered parenterally.

13. Use according to claim 12, characterized in that deoxypeganine is administered transdermally.

14. Use according to any one of the preceding claims, characterized in that the said schizophrenic psychosis is connected with increased monoamine oxidase activity and/or decreased functionality (decreased activity or decreased expression) of nicotinic acetylcholine receptors, especially of the alpha 7 subtype.

15. Use according to any one of the preceding claims, characterized in that the said derivative of deoxypeganine, as long as it is simultaneously inhibitor of acetylcholinesterase and of monoamine oxidase, is selected from the group consisting of 7-bromodeoxypeganine, 7-bromo-6-

hydroxy-5-methoxydeoxypeganine, 7-chloro-6-hydroxy-5-methoxydeoxypeganine, 7-fluoro-6-hydroxy-5-methoxydeoxypeganine, 7-iodo-6-hydroxy-5-methoxydeoxypeganine, 1,2,3,9-tetrahydro-6,7-methylenedioxypyrrolo[2,1-b]chinazoline and 2,3-dihydro-6,7-dimethoxypyrrolo[2,1-b]quinazoline-9(1H)-on.